| Date | Title | Description |
| 07.04.2025 | Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer | PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally... |
| 28.02.2025 | Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa | PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicin... |
| 06.02.2025 | Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 | PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024 financial results on Wed... |
| 14.01.2025 | Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer | PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally ... |
| 12.12.2024 | Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in ... | Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients
Both KB408 for AATD patients and KB407 for patients with cystic fibrosis were safe and well tolerated at all dosing regimens evaluat... |
| 12.11.2024 | Krystal Biotech to Present at Stifel 2024 Healthcare Conference | PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on Nove... |
| 06.11.2024 | Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference | PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovati... |
| 04.11.2024 | Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates | Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023
JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025
French health authority approved pre-marketing early reimbursed ... |
| 28.10.2024 | Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 | PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4... |
| 13.09.2024 | Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference | PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference... |
| 13.09.2024 | Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference | PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference... |
| 06.09.2024 | Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference | PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Inves... |
| 06.09.2024 | Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference | PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Inves... |
| 05.08.2024 | Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates | Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023
On track to deliver three clinical readouts in 2H 2024
Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024;
KB408 Phase 1 SERPE... |
| 05.08.2024 | Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates | Net product revenue of $70.3 million in 2Q and $166.2 million since launch in August 2023
On track to deliver three clinical readouts in 2H 2024
Jeune Aesthetics’ KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024;
KB408 Phase 1 SERPE... |
| 26.07.2024 | Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024 | PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5,... |
| 26.07.2024 | Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024 | PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5,... |
| 07.06.2024 | KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 | NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Mo... |
| 26.04.2024 | Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 | PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 20... |
| 08.02.2024 | Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa | • Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases
• Repeat administration of B-VEC eyedrops was well tolerated... |
| 03.07.2023 | Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis | /EIN News/ -- PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, a... |
| 22.05.2023 | Krystal Biotech Announces $160 Million Private Placement Equity Financing | /EIN News/ -- PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announ... |
| 22.05.2023 | Krystal Biotech Announces $160 Million Private Placement Equity Financing | - |
| 03.02.2022 | Power Moves: Krystal Biotech’s CBO hire marks continuing growth for Pittsburgh life sciences | Power Moves is a column where we chart the comings and goings of talent across the region. Got a new hire, gig or promotion? Email us: pittsburgh@technical.ly.Krystal Biotech hires a new chief business officer
Local gene therapy startup Kry... |
| 19.01.2022 | Krystal Biotech : Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors - Form 8-K | Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
January 18, 2022
PITTSBURGH, January 18, 2022 (GLOBE NEWSWIRE) - KrystalBiotech,Inc., ("Krystal")... |
| 01.12.2021 | Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock | PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public of... |
| 30.11.2021 | Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock | PITTSBURGH, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public of... |
| 30.11.2021 | Krystal Biotech : Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa - Form 8-K | Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of
VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
- Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and ... |
| 30.11.2021 | Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock | PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering ... |
| 29.11.2021 | Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock | PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering ... |
| 19.10.2021 | Krystal Biotech : Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis | PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharm... |
| 19.10.2021 | Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis | PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharm... |
| 14.10.2021 | Krystal Biotech : Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT | PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second gene... |
| 14.10.2021 | Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT | PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second gene... |
| 03.08.2021 | Krystal Biotech : Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality (Form 8-K) | Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase
1 trial to Assess Improvement in Skin Quality
- KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injection
- Initi... |
| 09.11.2020 | KRYSTAL BIOTECH, INC.
KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of th... |
| 11.09.2020 | KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of th... |
| 10.08.2020 | KRYSTAL BIOTECH, INC.
KRYSTAL BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) | The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of th... |
| 24.01.2020 | Deerfield vaults to the top of cell and gene therapy CDMO game with $1.1B facility at Philadelphia's newest biopharma hub | Back at the beginning of 2015, Deerfield Management co-led a $10 million Series C for a private gene therapy startup, reshaping the company and bringing in new leaders to pave way for an IPO just a year later.
Fast forwar... |
| 03.07.2019 | Epidermolysis bullosa: FDA seeks to help development of new treatments | The FDA recently released guidance to help companies develop new treatments for epidermolysis bullosa (EB), which is a debilitating and often fatal rare disease.
The six-page draft guidance offers details on consid... |
| 08.09.2017 | Term Sheet — Friday, September 8 | HOT TAKES
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
To the reader who said he would invest the $100K in “a massage therapy place as the Bay area has so much stress” — trust me, N... |
